BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28978230)

  • 1. A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers.
    Ramanathan R; King-Ahmad AJ; Holliman CL; Rodrigues AD
    Bioanalysis; 2017 Nov; 9(22):1787-1806. PubMed ID: 28978230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions.
    Njumbe Ediage E; Dillen L; Vroman A; Diels L; Kunze A; Snoeys J; Verhaeghe T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jan; 1073():80-89. PubMed ID: 29241088
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UHPLC-MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions.
    Kandoussi H; Zeng J; Shah K; Paterson P; Santockyte R; Kadiyala P; Shen H; Shipkova P; Langish R; Burrrell R; Easter J; Mariannino T; Marathe P; Lai Y; Zhang Y; Pillutla R
    Bioanalysis; 2018 May; 10(9):633-644. PubMed ID: 29749254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A fully automated and validated human plasma LC-MS/MS assay for endogenous OATP biomarkers coproporphyrin-I and coproporphyrin-III.
    King-Ahmad A; Clemens S; Ramanathan R; Zhang Y; Raha N; Zhang Y; Holliman C; Rodrigues AD; Li F
    Bioanalysis; 2018 May; 10(9):691-701. PubMed ID: 29747517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition.
    Lai Y; Mandlekar S; Shen H; Holenarsipur VK; Langish R; Rajanna P; Murugesan S; Gaud N; Selvam S; Date O; Cheng Y; Shipkova P; Dai J; Humphreys WG; Marathe P
    J Pharmacol Exp Ther; 2016 Sep; 358(3):397-404. PubMed ID: 27317801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III.
    Bednarczyk D; Boiselle C
    Xenobiotica; 2016; 46(5):457-66. PubMed ID: 26383540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous quantification of coproporphyrin-I and 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid in human plasma using ultra-high performance liquid chromatography coupled to tandem mass spectrometry.
    Suzuki Y; Sasamoto Y; Yoshijima C; Tanaka R; Ono H; Ando T; Shin T; Mimata H; Itoh H; Ohno K
    J Pharm Biomed Anal; 2020 May; 184():113202. PubMed ID: 32114159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Coproporphyrins As Endogenous Biomarkers for Organic Anion Transporting Polypeptide 1B Inhibition-Progress from 2016 to 2023.
    Lai Y
    Drug Metab Dispos; 2023 Aug; 51(8):950-961. PubMed ID: 37407093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coproporphyrin I Can Serve as an Endogenous Biomarker for OATP1B1 Inhibition: Assessment Using a Glecaprevir/Pibrentasvir Clinical Study.
    Kalluri HV; Kikuchi R; Coppola S; Schmidt J; Mohamed MF; Bow DAJ; Salem AH
    Clin Transl Sci; 2021 Jan; 14(1):373-381. PubMed ID: 33048456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multiplex HRMS assay for quantifying selected human plasma bile acids as candidate OATP biomarkers.
    Rago B; Tierney B; Rodrigues AD; L Holliman C; Ramanathan R
    Bioanalysis; 2018 May; 10(9):645-657. PubMed ID: 29749252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers.
    Yee SW; Giacomini MM; Shen H; Humphreys WG; Horng H; Brian W; Lai Y; Kroetz DL; Giacomini KM
    Clin Transl Sci; 2019 Jul; 12(4):388-399. PubMed ID: 30982223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition.
    Gu X; Wang L; Gan J; Fancher RM; Tian Y; Hong Y; Lai Y; Sinz M; Shen H
    Drug Metab Dispos; 2020 Aug; 48(8):724-734. PubMed ID: 32482623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug-Drug Interactions.
    Kunze A; Ediage EN; Dillen L; Monshouwer M; Snoeys J
    Clin Pharmacokinet; 2018 Dec; 57(12):1559-1570. PubMed ID: 29663259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further Evaluation of Coproporphyrins as Clinical Endogenous Markers for OATP1B.
    Feng S; Bo Q; Coleman HA; Charoin JE; Zhu M; Xiao J; Jin Y
    J Clin Pharmacol; 2021 Aug; 61(8):1027-1034. PubMed ID: 33460165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects.
    Shen H; Chen W; Drexler DM; Mandlekar S; Holenarsipur VK; Shields EE; Langish R; Sidik K; Gan J; Humphreys WG; Marathe P; Lai Y
    Drug Metab Dispos; 2017 Aug; 45(8):908-919. PubMed ID: 28576766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
    Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
    Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species.
    Shen H; Dai J; Liu T; Cheng Y; Chen W; Freeden C; Zhang Y; Humphreys WG; Marathe P; Lai Y
    J Pharmacol Exp Ther; 2016 May; 357(2):382-93. PubMed ID: 26907622
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3.
    Yoshikado T; Toshimoto K; Maeda K; Kusuhara H; Kimoto E; Rodrigues AD; Chiba K; Sugiyama Y
    CPT Pharmacometrics Syst Pharmacol; 2018 Nov; 7(11):739-747. PubMed ID: 30175555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects.
    Liu L; Cheeti S; Yoshida K; Choo E; Chen E; Chen B; Gates M; Singel S; Morley R; Ware J; Sahasranaman S
    J Clin Pharmacol; 2018 Nov; 58(11):1427-1435. PubMed ID: 29786857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substantially Increased Plasma Coproporphyrin-I Concentrations Associated With OATP1B1*15 Allele in Japanese General Population.
    Suzuki Y; Sasamoto Y; Koyama T; Yoshijima C; Nakatochi M; Kubo M; Momozawa Y; Uehara R; Ohno K
    Clin Transl Sci; 2021 Jan; 14(1):382-388. PubMed ID: 32961019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.